Arcus Biosciences, Inc. ( RCUS ) is a biopharmaceutical company that develops drugs designed to be used in combination with other agents, rather than as standalone treatments. RCUS is undergoing a strategic reset after the discontinuation of itsMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business M ...

Core Viewpoint - Arcus Biosciences, Inc. (RCUS) is undergoing a strategic reset following the discontinuation of its previous drug development strategy, focusing on combination therapies rather than standalone treatments [1]. Company Overview - RCUS is a biopharmaceutical company that specializes in developing drugs intended to be used in conjunction with other agents [1]. Strategic Changes - The company is implementing a strategic reset to adapt to the changing landscape of drug development and market needs [1].

Key Takeaways RCUS fell 14.4% after discontinuing the phase III STAR-221 study in upper GI cancers following OS data.The domvanalimab combo failed to beat nivolumab plus chemo on survival, though safety was comparable.RCUS will pivot focus to casdatifan and other oncology and I&I programs, with cash funding into 2028.Shares of Arcus Biosciences, Inc. (RCUS) , a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility ...

Citigroup maintains a "Buy" rating for Arcus Biosciences, Inc. (NYSE:RCUS) despite adjusting its price target from $56 to $44 following the discontinuation of the Phase 3 STAR-221 study.The STAR-221 study's discontinuation, due to lack of improved overall survival rates in cancer treatment, has led to a significant stock price decline of approximately 14.38%.Arcus Biosciences continues its research and development efforts, focusing on its inflammation and immunology portfolio despite recent setbacks.Arcus B ...

Core Viewpoint - Arcus Biosciences, Inc. is facing challenges following the discontinuation of its Phase 3 STAR-221 study, which has negatively impacted investor sentiment and stock performance, despite a previously strong market position. Group 1: Stock Performance - Truist Financial has set a price target of $30 for Arcus Biosciences (RCUS), indicating a potential upside of 34.74% from its current trading price of $22.27 [1][5] - Following the announcement of the study's discontinuation, RCUS stock experienced a significant decline, dropping to $21.77, a decrease of 13.42% or $3.38 from its previous value [2][3] - The stock fluctuated between $20.35 and $24 during the trading day, reflecting market volatility [3] Group 2: Study Discontinuation - Arcus announced the discontinuation of its Phase 3 STAR-221 study in collaboration with Gilead Sciences, as the Independent Data Monitoring Committee found no improvement in overall survival with the tested combination [2][5] - The decision to halt the study has adversely affected investor sentiment, despite the safety profiles being similar [2] Group 3: Future Focus - Arcus is shifting its focus to research and development investments in Casdatifan and its emerging inflammation and immunology portfolio [4][5] - The company's market capitalization is approximately $2.35 billion, with a trading volume of 5,619,062 shares on the day of the announcement [4]

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ:GILD) , due to futility. • Arcus Biosciences stock is among today’s weakest performers. Why is RCUS stock dropping?The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC) following its review of data from an event-driven, pre-specified interim analysis of overall survival (OS).STAR-221 evaluated ...

Arcus Biosciences, Inc. (RCUS) is trading 11.50 percent lower at $22.25, down $2.89 on Friday, after announcing the discontinuation of its Phase 3 STAR-221 study conducted with Gilead Sciences. The stock opened at $21.15 and has traded between $20.35 and $24.00 so far on the New York Stock Exchange. The bid sits at $22.54 and the ask at $22.60, with volume at 4,426,823 versus an average of 1,561,846.Arcus shares are now trading well off their recent peak, within a 52-week range of $6.50 to $26.40. For comm ...

Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers afte... ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc., due to futility. The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC). ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...